Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-26,301
Closed -$2.65M 363
2025
Q2
$2.65M Buy
26,301
+874
+3% +$66.8K 0.07% 122
2025
Q1
$1.94M Sell
25,427
-1,188
-4% -$90.9K 0.05% 127
2024
Q4
$1.84M Buy
26,615
+4,796
+22% +$345K 0.05% 163
2024
Q3
$1.59M Buy
21,819
+7,650
+54% +$565K 0.04% 207
2024
Q2
$949K Sell
14,169
-39,338
-74% -$1.53M 0.03% 305
2024
Q1
$1.45M Sell
53,507
-3,220
-6% -$90.1K 0.04% 236
2023
Q4
$1.76M Sell
56,727
-2,565
-4% -$66.5K 0.06% 189
2023
Q3
$1.5M Sell
59,292
-53,000
-47% -$1.21M 0.03% 285
2023
Q2
$2.37M Sell
112,292
-99,048
-47% -$1.88M 0.05% 259
2023
Q1
$3.6M Buy
211,340
+35,588
+20% +$691K 0.09% 186
2022
Q4
$3.51M Buy
175,752
+58,908
+50% +$1.14M 0.06% 284
2022
Q3
$2.52M Sell
116,844
-32,000
-21% -$767K 0.03% 494
2022
Q2
$2.94M Buy
148,844
+73,844
+98% +$1.55M 0.03% 469
2022
Q1
$1.76M Buy
+75,000
New +$1.74M 0.02% 615
2019
Q3
Sell
-40,000
Closed -$1.02M 341
2019
Q2
$1.02M Buy
+40,000
New +$1.11M 0.02% 173
2017
Q4
Sell
-82,858
Closed -$2.59M 331
2017
Q3
$2.59M Buy
+82,858
New +$1.58M 0.04% 245
2015
Q2
Sell
-401,674
Closed -$8.35M 861
2015
Q1
$8.35M Buy
401,674
+371,674
+1,239% +$6.55M 0.08% 241
2014
Q4
$464K Sell
30,000
-47,573
-61% -$675K 0.01% 433
2014
Q3
$1.01M Buy
+77,573
New +$1.17M 0.02% 345

Other funds holding INSM

UBS O'Connor's INSM Position: Q3 2025 in Review

UBS O'Connor sold out of Insmed (INSM) in Q3 2025, closing a stake of 26,301 shares — an estimated $2.65M sold.

UBS O'Connor first reported a position in INSM in Q3 2014 and held it in 19 quarters. The position peaked at $8.35M in Q1 2015. 566 funds tracked by Wall St. Rank hold INSM as of Q3 2025.

  • UBS O'Connor reported no remaining Insmed position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 26,301 Insmed shares in Q3 2025, an estimated $2.65M.
  • UBS O'Connor first reported a position in Insmed in Q3 2014 and held it in 19 quarters.
  • UBS O'Connor's Insmed position peaked at $8.35M in Q1 2015.
  • 566 funds tracked by Wall St. Rank held Insmed as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.